EUDA Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeValuation
- Forward P/E
- 11.30
- PEG ratio
- —
- P/B
- —
- P/S (TTM)
- 8.24
- EV/EBITDA
- -25.90
Profitability & growth
- ROE (TTM)
- 0.0%
- Operating margin
- -34.8%
- Revenue growth YoY
- 78.9%
- Dividend yield
- —
- Beta
- 0.56
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About EUDA Health Holdings Limited
Company profileEUDA Health Holdings Limited is a biopharmaceutical innovator dedicated to the discovery, development, and commercialization of transformative therapies for rare diseases and unmet medical needs. The company utilizes cutting-edge technologies and maintains a strong clinical pipeline, emphasizing supportive care and immune modulation. With a deep commitment to research and development, EUDA is strategically positioned to drive healthcare advancements, improve patient outcomes, and broaden access to vital medical treatments.
Classification
- Sector
- Real Estate
- Industry
- Real Estate Services
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 60 KAKI BUKIT PLACE, SINGAPORE, SINGAPORE
- Fiscal year end
- December
- Latest quarter
- Sep 30, 2025
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
I'm your AI thinking companion for the markets — I can help you explore and learn, but I'm not a financial advisor. Everything here is educational. Disclaimer